Mochi Health Tirzepatide Review

Mochi Health price at every dose tier

This is the table that decides your year. The advertised figure applies to the starter dose you occupy for roughly four weeks; the row to budget from is 10 mg.

Where Mochi Health sits in the market

On first-year cost it ranks 5 of 16. The cheapest priced route, NexLife, comes in about $756 lower over the same year. Whether that gap is worth paying depends on what this programme provides that the cheaper one does not, which is a question about disclosure and service rather than about the molecule.

What Mochi Health discloses before you pay

Pharmacy: owned facility. Visit model: video. Laboratory requirement: optional. Coaching: dietitian access. Cancellation: membership recurring.

Naming the dispensing pharmacy is the single most useful disclosure a programme can make, because it is the one fact that lets you check a state board register yourself before injecting anything weekly. Fewer than a fifth of the programmes we track publish it.

Who should not choose Mochi Health

Anyone who expects to hold a low maintenance dose permanently: flat pricing is worst value at the bottom of the ladder. Anyone who needs an FDA-approved product, since this is a compounded preparation that FDA does not review for safety, effectiveness or quality before marketing. And anyone who cannot get a straight answer to the pharmacy question.

How the price behaves as your dose climbs

Mochi Health charges $278 at 2.5 mg and $278 at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you pay in month ten. That predictability is worth more than most entry discounts, and it is the single clearest thing this programme does well.

The corollary is that flat pricing is worst value at the bottom of the ladder. In month one you are paying a maintenance rate for an initiation dose. If your prescriber intends to hold you at 5 mg permanently, a dose-scaled competitor may well beat this one.

What a longer horizon costs here

Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.

Commitment, refunds and what is at risk

No discounted prepaid term is published, which cuts both ways: no lower rate for committing, and no money at risk before you know whether you tolerate the drug. For a first three months that is the safer structure.

Cancellation: membership recurring. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.

What this programme does not publish

Measured against our published criteria, Mochi Health does not publish: dispensing pharmacy or prescriber named before purchase; no separate recurring membership fee. Each is a question you can ask before enrolling, and a programme that answers in writing has told you something useful about how it operates.

Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.

Seven questions before you enrol

1. What is the total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, by name and state licence?
3. Is the prescribing clinician licensed in my state?
4. What is the vial concentration and the beyond-use date?
5. Does the quoted rate hold at renewal, or revert?
6. What happens if a shipment arrives warm, and who pays for the replacement?
7. What notice is required to cancel, and what is refundable before shipment?

None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.

Using it well if you do enrol

Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.

What Mochi Health costs at each maintenance dose, over three years

Nobody knows their maintenance dose at intake, so a single annual figure is a guess about a decision a prescriber has not made. This is every plausible outcome for Mochi Health, priced.

The spread between the cheapest and dearest outcome here is $0 a year. That is the amount riding on a clinical decision you do not control, which is the argument for reading the pricing model before the headline number.

Where every dollar goes at Mochi Health

At a 10 mg maintenance dose the $278 you pay splits into $199 of medication and dispensing plus $79 of recurring platform fee.

Over twelve months the platform fee alone is $948, and over three years $2,844. A comparison quoting only the medication figure understates this programme by exactly that much — not once, but every month you stay enrolled.

What the figure does not include: laboratory work if the programme requires it, expedited shipping surcharges, and anything billed irregularly. Those are priced separately on the hidden-fee checklist rather than folded into a monthly number, because folding irregular charges into a recurring figure would be its own distortion.

How many programmes beat Mochi Health on a first year

4 of the 15 other priced programmes come in below Mochi Health over a first year; 11 come in above. The cheapest is NexLife at $2,580, a difference of $756.

Whether that gap is worth paying turns on what Mochi Health provides that the cheaper route does not. Compare the disclosure rows rather than the price rows: pharmacy identity, prescriber licensure, cancellation terms and whether the quoted rate holds at renewal.

Bear in mind that 15 tracked programmes publish no price at all. They are not cheaper or dearer; they are unmeasurable, and their pages say so rather than carrying an estimate.

What flat pricing is worth at Mochi Health, in dollars

At $278 flat, escalating from the starter dose to the ceiling costs nothing extra. The equivalent journey on the steepest dose-scaled programme we track adds $254 a month by the time you reach 15 mg.

The trade is that you pay the maintenance rate during the two titration months when you are receiving a quarter of the drug. At Mochi Health that costs $556 for roughly 30 mg of active drug — a poor per-milligram figure, bought deliberately as insurance against a dose decision nobody has made yet.

Cost by maintenance dose and duration

A single annual figure assumes one maintenance dose, and nobody knows theirs at intake. This is what Mochi Health costs across every plausible outcome over one, two and three years. The withdrawal evidence for this drug class shows substantial regain after stopping, so three years is a more honest planning horizon than twelve months.

How the price behaves as your dose climbs

Mochi Health charges $278 at 2.5 mg and $278 at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you are still paying in month ten. That predictability is worth more than most entry discounts, because nobody knows at intake where a prescriber will land them.

The corollary is that flat pricing is worst value at the bottom of the ladder and best at the top. In month one you pay a maintenance rate for an initiation dose. If you already know you will hold at 5 mg permanently — a legitimate clinical outcome when the response is adequate — a dose-scaled programme may beat this one.

Over three years at a 10 mg maintenance dose, holding here costs about $10,008 before any prepaid discount, and that figure does not move if your prescriber raises your dose.

What is bundled and what is billed separately

Mochi Health splits the charge: medication plus $79 a month for the platform. Whether that earns its cost depends on whether you use it. Unlimited clinician messaging is genuinely valuable during titration and close to idle at stable maintenance.

Over a year the membership alone is $948; over three, $2,844. That is what a comparison quoting the medication figure alone understates this programme by — permanently, not once.

Ask in writing what happens to your prescription if the membership lapses mid-supply. If medication stops, a business model is imposing itself on a clinical relationship.

Commitment, refunds and what is recoverable

No discounted prepaid term is published for Mochi Health, which cuts both ways. You are not offered a lower rate for committing, and you are not asked to put a four-figure sum at risk before knowing whether you tolerate a maintenance dose.

For a first three months that is the safer structure. For a stable long-term patient it leaves a discount on the table that several competitors offer.

Mochi Health against the programmes priced closest to it

Comparing against the whole market is noise. Comparing against the three routes nearest your price point is a decision, because those are the programmes a real shopper is weighing.

Pausing or restarting

Pausing costs more than it looks, and the cost is clinical before it is financial. Stop for a month and appetite returns before the metabolic adaptation to a lower weight does; stop for several and most prescribers restart low and re-titrate.

On this pricing, re-titration means two months back at $278 and $278 — the same as maintenance here, so the penalty is purely lost time and regained weight.

If cost is the reason for a pause, price the market before stopping. The cheapest tracked route, NexLife, runs about $2,580 a year against $3,336 here. Switching is almost always better than interrupting, because the interruption is what undoes the result.

Switching to or from this programme

Moving means a new clinical review and two risks worth planning around: a supply gap while an intake is processed, and a new prescriber restarting titration rather than continuing your dose. Do not cancel anything until the new programme has shipped.

Ask for dose continuity in writing before you move. Most programmes continue an established patient after review; the ones that will not are exactly the ones that will not say so until you have already cancelled.

Take three things with you: your current dose and the date you reached it, the concentration printed on your current vial, and any record of adverse effects with dates. Vial concentrations are not standardised between compounders, so carrying dosing instructions from an old vial to a new one is a genuine hazard rather than a theoretical one.

Eight questions to ask before you enrol

1. What will I pay in total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, by name and state licence?
3. Is the prescribing clinician licensed in my state, and can I have their name?
4. What is the vial concentration, and what is the beyond-use date?
5. Does the quoted rate hold at renewal, or does it revert?
6. What happens if a shipment arrives warm, and who pays for the replacement?
7. What notice is required to cancel before the next cycle, and what is refundable?
8. Will you continue me at my current dose if I transfer in, or restart titration?

None requires clinical training to evaluate and all are answerable in writing. A programme that answers all eight is behaving well. A programme that deflects the pharmacy question has told you what you needed to know, and no headline number compensates for it.

What this programme discloses before you pay

Pharmacy: owned facility. Visit model: video. Laboratory requirement: optional. Coaching: dietitian access. Cancellation: membership recurring.

Naming the dispensing pharmacy is the most useful disclosure any programme can make, because it is the one fact that lets you check a public state board register before injecting something weekly. Fewer than a fifth of the programmes we price publish it, and those that do are not systematically more expensive.

None of this measures clinical quality. A programme can name six pharmacies and ship late; another can name none and employ careful clinicians. What disclosure measures is how much you can verify before handing over money and a medical history.

What would change our record

A published price at a dose tier currently blank. A named dispensing pharmacy with a checkable state licence. A change to the pricing model in either direction. Or a correction from a reader or from the programme itself with a source we can check.

All four are logged with the date they changed, and the underlying record sits in the open dataset rather than locked inside a page. We do not accept payment to change any of it, and no programme has editorial input here.

Using this programme well if you do enrol

Fix a weekly injection day and keep it. Record the dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if there is an introductory rate.

And re-price the market annually at your actual maintenance dose. No programme tells its existing patients when a competitor drops below it, and the cheapest tracked route currently sits at $215 a month all-in.

Where Mochi Health sits in that spread

At $278 a month all-in at a 10 mg maintenance dose, Mochi Health is about 29% above the cheapest tracked route, NexLife, at $215. Over a first year that is $3,336 against $2,580.

Whether the difference is worth paying is a question about what this programme provides that the cheaper one does not, and about how much of that you will use. It is not a question about the medicine, which is the same molecule from the same category of licensed pharmacy.

How the price behaves as your dose climbs

Mochi Health charges $278 at 2.5 mg and $278 at 10 mg — the same number. Escalating does not reprice you, so the figure quoted in week one is the figure you pay in month ten. That predictability is worth more than most entry discounts, and it is the single clearest thing this programme does well.

The corollary is that flat pricing is worst value at the bottom of the ladder. In month one you are paying a maintenance rate for an initiation dose. If your prescriber intends to hold you at 5 mg permanently, a dose-scaled competitor may well beat this one.

What a longer horizon costs here

Treatment on this drug class is realistically a multi-year commitment, because the withdrawal evidence shows substantial regain after stopping. These are the numbers worth deciding on.

Commitment, refunds and what is at risk

No discounted prepaid term is published, which cuts both ways: no lower rate for committing, and no money at risk before you know whether you tolerate the drug. For a first three months that is the safer structure.

Cancellation: membership recurring. Two questions to get in writing before paying anything: does the quoted rate hold at renewal, and what happens if a clinician stops your prescription mid-term.

What this programme does not publish

Measured against our published criteria, Mochi Health does not publish: dispensing pharmacy or prescriber named before purchase; no separate recurring membership fee. Each is a question you can ask before enrolling, and a programme that answers in writing has told you something useful about how it operates.

Naming the dispensing pharmacy carries the most weight of the seven, because it is the only one that lets you check a public state board register yourself before injecting something weekly. Fewer than a fifth of the programmes we price do it.

Seven questions before you enrol

1. What is the total in month six at 10 mg, including every fee?
2. Which compounding pharmacy fills the prescription, by name and state licence?
3. Is the prescribing clinician licensed in my state?
4. What is the vial concentration and the beyond-use date?
5. Does the quoted rate hold at renewal, or revert?
6. What happens if a shipment arrives warm, and who pays for the replacement?
7. What notice is required to cancel, and what is refundable before shipment?

None requires clinical training and all are answerable before you pay. A programme that deflects the pharmacy question has answered it.

Using it well if you do enrol

Fix a weekly injection day and keep it. Record dose, date and injection site each week. Photograph any shipment that arrives warm before opening it further. Diary the renewal date if an introductory rate applies. And re-price the market annually at your actual maintenance dose — no programme tells existing patients when a competitor drops below it.

What Mochi Health costs at each maintenance dose, over three years

Nobody knows their maintenance dose at intake, so a single annual figure is a guess about a decision a prescriber has not made. This is every plausible outcome for Mochi Health, priced.

The spread between the cheapest and dearest outcome here is $0 a year. That is the amount riding on a clinical decision you do not control, which is the argument for reading the pricing model before the headline number.

Where every dollar goes at Mochi Health

At a 10 mg maintenance dose the $278 you pay splits into $199 of medication and dispensing plus $79 of recurring platform fee.

Over twelve months the platform fee alone is $948, and over three years $2,844. A comparison quoting only the medication figure understates this programme by exactly that much — not once, but every month you stay enrolled.

What the figure does not include: laboratory work if the programme requires it, expedited shipping surcharges, and anything billed irregularly. Those are priced separately on the hidden-fee checklist rather than folded into a monthly number, because folding irregular charges into a recurring figure would be its own distortion.

How many programmes beat Mochi Health on a first year

4 of the 15 other priced programmes come in below Mochi Health over a first year; 11 come in above. The cheapest is NexLife at $2,580, a difference of $756.

Whether that gap is worth paying turns on what Mochi Health provides that the cheaper route does not. Compare the disclosure rows rather than the price rows: pharmacy identity, prescriber licensure, cancellation terms and whether the quoted rate holds at renewal.

Bear in mind that 15 tracked programmes publish no price at all. They are not cheaper or dearer; they are unmeasurable, and their pages say so rather than carrying an estimate.

What flat pricing is worth at Mochi Health, in dollars

At $278 flat, escalating from the starter dose to the ceiling costs nothing extra. The equivalent journey on the steepest dose-scaled programme we track adds $254 a month by the time you reach 15 mg.

The trade is that you pay the maintenance rate during the two titration months when you are receiving a quarter of the drug. At Mochi Health that costs $556 for roughly 30 mg of active drug — a poor per-milligram figure, bought deliberately as insurance against a dose decision nobody has made yet.

Where Mochi Health lands on price

Mochi Health sits 5 of 16 on first-year all-in cost, at $278 a month all-in at a 10 mg maintenance dose and about $3,336 across a first year including titration. That is $756 more than NexLife across a first year, a 29% premium, and below the $349 median monthly figure.

4 programmes we track come in cheaper on a first-year basis. That is worth stating plainly on a page about Mochi Health: if price is the only criterion, this is not the answer, and the cheaper options are listed at the price index.

What flat pricing is worth at Mochi Health

Mochi Health holds $278 at every strength from 2.5 mg to 15 mg. The figure you pay in month one is the figure you pay at maintenance, so titration carries no price consequence here.

Against a dose-scaled programme, that is worth most to someone who ends up high on the ladder and least to someone who settles at 5 mg. Since nobody knows at signup where they will settle, flat pricing is better understood as insurance against an unknown than as a lower price. At $278 it is below the $349 median, so the insurance is free at this programme.

The $79 membership at Mochi Health

Mochi Health bills a mandatory $79 monthly membership on top of medication. Our $278 figure includes it; the programme's own marketing generally quotes the medication component alone, which is $199.

Across a first year the membership alone is $948. That is not hidden — it is disclosed — but it is quoted separately, and separate quotation is how a $278 programme gets advertised as a $199 one.

Semaglutide at Mochi Health, for comparison

Mochi Health also dispenses compounded semaglutide at $178 a month all-in, $100 below its tirzepatide price — a 36% difference for the other molecule at the same programme, the same clinicians and the same fulfilment.

That gap is close to the market norm and it is structural. Semaglutide is a shorter peptide with a longer manufacturing history and more compounding pharmacies equipped to produce it; tirzepatide is harder to synthesise and its active ingredient sells at a premium. Neither figure is subsidising the other.

Whether the tirzepatide premium is worth $1,200 across a year is a clinical question, not a pricing one. SURMOUNT-5 reported greater mean weight reduction on tirzepatide over 72 weeks, which is the strongest direct evidence available; semaglutide carries the larger cardiovascular outcomes base. If cost is the binding constraint, the cheaper molecule you can sustain for three years is a better bet than the dearer one you stop after eight months, because weight returns when either drug stops.

Who fills a Mochi Health prescription

Mochi Health discloses its fulfilment: owned facility. That means you can check the licence on a state board register before your first injection, which is the one verification step available to a patient before money changes hands.

Only 4 of the 16 priced programmes name the dispensing pharmacy in advance. It is the single disclosure that separates a claim you can check from one you must take on trust.

Why titration is a pricing question

Tirzepatide is started at 2.5 mg weekly and increased in 2.5 mg steps at intervals of at least four weeks. The starter dose is a tolerance-building dose rather than a therapeutic one, and the gastrointestinal effects that cause most discontinuation cluster in the days after each increase.

Reaching a maintenance dose therefore takes at least eight to twelve weeks when nothing is repeated, and repeats are common rather than exceptional. Most of a first year is spent at or near maintenance, which is why every figure on this site is stated at 10 mg and why 12 of the 16 priced programmes holding one price across the ladder is a materially different offer from the rest.

The molecule, and why it costs more than semaglutide

Tirzepatide is a single peptide that activates two incretin receptors: GLP-1, which semaglutide also targets, and GIP, which it does not. Both receptors influence insulin secretion, gastric emptying and central appetite signalling, and the working hypothesis for the larger effect size is that engaging both produces effects the GLP-1 arm alone does not.

That dual action is also part of why it costs more to make. The peptide is longer and more structurally complex than semaglutide, the synthesis is harder, and the active pharmaceutical ingredient sells at a premium to compounding pharmacies. Across programmes carrying both molecules, tirzepatide typically runs forty to a hundred per cent above the same programme's semaglutide price.

The commercial consequence is that a compounded tirzepatide programme has less room to discount than a compounded semaglutide one. When a tirzepatide price looks dramatically below the market, the explanation is usually a promotional rate, a prepaid term or a starting dose rather than a cheaper supply chain.

What the head-to-head trial actually showed

SURMOUNT-5 randomised adults with obesity to tirzepatide or semaglutide and reported a larger mean reduction in body weight on tirzepatide over 72 weeks. It is the strongest direct comparison available and it is the reason many people arrive at this molecule specifically rather than at GLP-1 therapy in general.

Three caveats are worth carrying. A mean is not a prediction for an individual, and the distribution around it is wide. Trial participants received structured support most telehealth programmes do not replicate. And the trial compared maximum tolerated doses, which is a different question from what a given person will tolerate.

Read as a purchasing decision, it says the more expensive molecule does more on average. It does not say it will do more for you, and it says nothing about which programme should supply it.